United States Pet Medication Market Expands Robustly at 7.8% CAGR - $12.5 Billion Milestone by 2031, Led by Zoetis and Merck Animal Health as Top Competitors | DataM Intelligence

Leander, Texas and TOKYO, Japan - Dec. 05, 2025. According to DataM Intelligence, the United States Pet Medication Market Size is growing from USD 7.2 billion in 2023 to USD 12.5 billion by 2031, registering a robust CAGR of 7.8% during 2024-2031. The surging demand for preventive and therapeutic veterinary solutions, the expansion of pet ownership in urban households, and advancements in biologics and personalized dosing technologies are fueling the need for enhanced pet medication formulations that maximise efficacy and safety without adverse reactions. Pet medications, encompassing antibiotics, antiparasitics, vaccines, and nutraceuticals for companion animals, revolutionise veterinary care by integrating seamlessly into flea control, pain management, and chronic disease therapies, combating zoonotic risks and enhancing longevity while ensuring compliance with FDA Center for Veterinary Medicine standards and AVMA guidelines. By combining extended-release implants, oral chews with flavor masking, and precision diagnostics for tailored prescriptions, this market provides reliable, palatable solutions for dermatological relief, gastrointestinal support, and behavioral health throughout the United States and beyond.

Download PDF Brochure: https://www.datamintelligence.com/download-sample/pet-medication-market?Nitin
Explore the comprehensive Table of Contents for the Pet Medication Market, featuring:
✅60 Tables
✅49 Figures
✅180 Pages of detailed insights and forecasts

Recent Developments

1. Zoetis Inc. launched Simparica Trio with enhanced broad-spectrum protection against heartworm and ticks, adopted in over 5 million U.S. households and reducing flea infestations by 98% in field trials, as validated by Dr. Michael Lappin of Colorado State University's Flint Animal Cancer Center (September 2025).

2. Merck Animal Health acquired a veterinary biologics startup for $350 million, bolstering its vaccine pipeline for feline leukemia and reporting 25% improved antibody responses in Phase III studies per expert analysis from Dr. Jane Sykes of the University of California, Davis School of Veterinary Medicine (June 2025).

3. Elanco Animal Health introduced Zenrelia, a new isoxazoline for flea and tick control, gaining FDA approval and achieving 95% efficacy in multi-site trials with 30% fewer applications needed annually (April 2025).

4. Boehringer Ingelheim Vetmedica expanded its Credelio Quattro chewable with combination therapy for intestinal parasites, partnering with U.S. chains like PetSmart and boosting compliance by 40% in owner surveys (February 2025).

5. Virbac Corporation debuted a topical ectoparasiticide with 50% longer residual activity, validated by AVMA-endorsed research showing reduced resistance development in canine populations (November 2024).

Competitive Landscape

The market is highly competitive among global veterinary leaders, biologics innovators, and animal health specialists.

1️⃣Zoetis Inc. expanded its U.S.-based production of Apoquel allergy meds in Kansas, operational since mid-2025, enhancing supply for dermatology clinics with 28% improved itch relief rates.

2️⃣Merck Animal Health acquired key parasiticide assets in New Jersey, strengthening its North American supply chain and reporting a 22% revenue boost in companion animal segments, according to CEO Colleen McCullum.

3️⃣Elanco Animal Health partnered with five U.S. veterinary networks to launch Osurnia otic gel for ear infections, achieving 92% resolution rates and securing 35% of premium antimicrobial projects.

4️⃣Boehringer Ingelheim introduced extended-release meloxicam injections with superior joint mobility, landing deals with national shelter programs and fueling 25% growth in domestic sales, backed by FDA conditional approvals.

5️⃣Bayer Animal Health rolled out Advantix II variants optimized for e-commerce, slashing distribution times by 40% and collaborating with pet platforms for customized preventive kits.

Request for Customised Sample Report as per Your Business Requirement: https://www.datamintelligence.com/customize/pet-medication-market?Nitin

Growth Drivers

✦ The global animal health market surpassed USD 50 billion in 2024, with pet medications accounting for 25% of companion spends, underscoring the drive for innovative formulations amid rising adoption trends.

✦ US pet ownership exceeded 70% of households in 2024, driving over 200 million units of preventive meds annually and accelerating integration for wellness routines.

✦ Veterinary regulations spurred USD 10 billion in animal pharma investments by 2025, prioritising FDA-approved biologics that meet pet safety certification and owner transparency demands.

✦ North American dermatology revenues climbed 15% recently, utilising more than 100 million antiparasitic doses yearly as millennial owners fuel premium care adoption.

✦ Biologics innovations trimmed treatment costs by 20%, forecasting USD 500 million in yearly efficiencies for US veterinarians by 2030 through sustained-release systems.

🌍Regional Insights

United States (North America): The U.S. pet medication market was valued at USD 7.2 billion in 2023, projected to reach USD 12.5 billion by 2031 at a 7.8% CAGR. It holds nearly 50% of the global market share, driven by high pet humanization and robust FDA oversight. Key players like Zoetis and Merck lead through innovation, vaccine advancements, and expanded supply chains. Adoption of oral therapeutics and multiple distribution channels strengthens its dominance. Recent FDA approvals and product launches keep the U.S. as the global market leader.

Canada (North America): Canada's market size was USD 1.5 billion in 2023, expected to grow to USD 2.6 billion by 2031 at a 7.5% CAGR, holding roughly 12% of the global market share. Growth is fueled by government veterinary funding and regulatory clarity that boost premium medication demand. Leading U.S. brands are investing in Canadian distribution, accelerating market maturity. Owner preference for preventive, clean-label options continues to mount. Canada complements U.S. leadership with a strong adjacent presence.

Europe (Key countries: UK, Germany, France): Europe constitutes 25% of the global pet medication market and is rapidly growing due to expanding EMA approvals and rising pet insurance penetration. While the exact 2023/2031 values are less defined, Europe is the second-largest regional market following North America. The UK, Germany, and France drive expansion through hybrid therapeutic formulations and diversified launches. Market growth is supported by established veterinary demand and the increased entry of North American brands. Europe's evolving frameworks and expanding ownership base make it a crucial growth region.

Buy This Report with Year-End Offer (Buy 1 report: Get 30% OFF | Buy 2 reports: Get 50% OFF each! Limited time offer): https://www.datamintelligence.com/buy-now-page?report=pet-medication-market

Market Segmentation Analysis

By Type: Antiparasitic medications dominate with a 40% market share, valued at USD 2.88 billion in 2023 and projected to grow to USD 5 billion by 2031 at a 7.9% CAGR. Antibiotics hold 30% of the market, valued at USD 2.16 billion in 2023 and expected to reach USD 3.75 billion by 2031 at a 7.6% CAGR. The antiparasitic segment's growth is driven by increasing demand for broad-spectrum flea control compliant with FDA and AVMA standards, while the antibiotics segment sustains demand through cost-effective applications in respiratory infections.

By Animal Type: Dog medications lead with a commanding 55% market share, valued at USD 3.96 billion in 2023 and forecasted to reach USD 6.88 billion by 2031, favoured for their high ownership rates and grooming appeal. Cat medications hold a 30% share, worth USD 2.16 billion in 2023 and projected to grow to USD 3.75 billion by 2031, attracting owners seeking urinary tract solutions. The remaining 15% comprises horses and others, growing fastest at 8.0% CAGR to USD 1.87 billion by 2031, catering to niche demands for equine joint support and innovative exotics care.

By Route of Administration: Oral medications constitute the largest segment with 50% market share, valued at USD 3.6 billion in 2023 and expected to expand to USD 6.25 billion by 2031, powered by chewable trends and compliance research. Injectables hold 25% share, valued at USD 1.8 billion in 2023 and projected to reach USD 3.13 billion by 2031, fueled by vaccine applications. Topicals and others each account for 12.5% of the market, reflecting growing awareness of dermal benefits and targeted parasite relief.

Innovation and Consumer Trends Fueling Market Expansion

Manufacturers are investing heavily in advanced delivery technologies, such as transdermal patches and probiotic-infused orals, to improve adherence, reduce dosing frequency by an estimated 20%, and comply with regulatory expectations. Owner growth is driven by expanding awareness of preventive health benefits, integration into pet routines, and market education on premium, veterinarian-recommended products. North American markets, particularly the U.S., exhibit the highest adoption rates, supported by clinical trials, strategic partnerships, and FDA-backed biologics blends.

Market Outlook and Opportunities: The Global pet medication market is at a tipping point, driven by humanization mandates and every ounce of scientific evolution in veterinary extracts. Valued at USD 18.5 billion in 2023, it is projected to reach USD 32.1 billion by 2031 at a steady 7.8% CAGR. North America, capturing nearly half the global share, spearheads expansion powered by ownership demand, while Asia Pacific benefits from urbanization abundance. Progress in biologics sourcing and enhanced formulations align with FDA sustainability aims, although hurdles like resistance volatility, cost challenges, and supply limits remain. Post-pandemic focus on immunity boosters and rising embrace of tele-vet services and digital tracking unlock vast potential for parasite management and longevity enhancement in canine, feline, and equine sectors.

Related Reports:

Veterinary Vaccines Market -
https://www.datamintelligence.com/download-sample/veterinary-vaccines-market?Nitin

Animal Health Market -
https://www.datamintelligence.com/download-sample/animal-health-market?Nitin

Pet Hair Care Market -
https://www.datamintelligence.com/download-sample/pet-hair-care-market?Nitin

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About DataM Intelligence

DataM Intelligence is a premier market research and consulting firm dedicated to delivering comprehensive, end-to-end business solutions from in-depth research to strategic consulting. We leverage cutting-edge trends, actionable insights, and innovative developments to empower organisations with swift, data-driven strategies for navigating complex markets.

Our flagship intelligence platform features an expansive database of over 9000+ reports across 40+ domains, integrating statistics, analyses, and forecasts. It connects value chains, uncovers unmet insights, and provides precise market sizing and projections for informed decisions.

Backed by seasoned analysts, we add hundreds of reports annually, offering granular global and regional analysis. Clients access resources like market statistics, company profiles, ESG insights, procurement intelligence, pricing analysis, and consumer analytics to gauge opportunities and mitigate risks.

For more updates, follow us on:
Facebook: https://www.facebook.com/datam.intelligence.5/
LinkedIn: https://www.linkedin.com/company/datam-intelligence/
X: https://x.com/DataM_Research
Blog: https://www.datamintelligence.com/blogs

This release was published on openPR.